Patents by Inventor Daniel Baty

Daniel Baty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE-DOMAIN ANTIBODY BINDING TO THE G PROTEIN ALPHA
    Publication number: 20210309739
    Abstract: The present invention relates to a single-domain antibody (sdAb) which binds to the G protein alpha, comprising an amino acid sequence consisting of 3 CDR regions (CDR1 to CDR3) and 4 hinge regions (FR1 to FR4) according to the following formula (I): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I) and advantageously having a dissociation constant (Kd), measured in FRET, of less than 100 nM.
    Type: Application
    Filed: July 26, 2019
    Publication date: October 7, 2021
    Inventors: Thomas Fabien Michel ROUX, Elodie Julie DUPUIS, Eric Jacques Christian TRINQUET, Mélanie DA SILVA, Camille S. MAILHAC, Patrick JM CHAMES, Daniel BATY, Julien Jean-Marius SOULE, Philippe RONDARD, Jean-Philippe R. PIN
  • Production of antibody formats and immunological applications of said formats
    Patent number: 10385137
    Abstract: The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val D'Aurelle, Institut Paoli Calmettes
    Inventors: Daniel Baty, Ghislaine Behar, Martine Mansais, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • METHODS FOR SELECTING BINDERS BY PHAGE DISPLAY AND MASKED SELECTION
    Publication number: 20190249170
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in the presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Inventors: Daniel BATY, Patrick CHAMES
  • ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20190202932
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Methods for selecting binders by phage display and masked selection
    Patent number: 10316315
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 11, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Anti-EGFR conformational single domain antibodies and uses thereof
    Patent number: 10287360
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 14, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université d' Aix-Marseille, Centre National de la Recherche Scientifique (CNRS), CISBIO Bioassays, Institut Jean Paoli & Irene Calmettes
    Inventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
  • Anti-mGluR2 conformational single domain antibodies and uses thereof
    Patent number: 10174115
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUD
    Inventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
  • Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
    Patent number: 10174117
    Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Daniel Baty, Patrick Chames, Brigitte Kerfelec, Marc Turini
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 10167345
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: January 1, 2019
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • ANTI- NKG2D SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20180327499
    Abstract: The present invention relates to anti-Natural Killer Group 2 member D (NKG2D) single domain antibodies and uses thereof in particular in the therapeutic field.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 15, 2018
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (CNRS)
    Inventors: Daniel BATY, Patrick CHAMES, Brigitte KERFELEC, Elise TERMINE
  • ANTI-MESOTHELIN ANTIBODIES AND USES THEREOF
    Publication number: 20180002439
    Abstract: The present disclosure provides isolated nanobodies based on camelid VHH domains that specifically bind to mesothelin with high affinity. Also disclosed are conjugate constructs comprising the isolated nanobodies derivatized to allow conjugation to or that are conjugated to accessory moieties, such as biologically active moieties (e.g., a cytotoxin, a non-cytotoxic drug, a radioactive agent, a protein, or an enzyme) or detectable markers (e.g., a fluorescent label or biotin). Nucleic acid molecules encoding the nanobodies and conjugate constructs, expression vectors, host cells and methods for expressing the nanobodies and conjugate constructs are also provided. Pharmaceutical compositions comprising the nanobodies and conjugate-constructs as described herein are also provided. The present invention is also directed to methods for detecting mesothelin, as well as methods for diagnosis, treating, preventing and ameliorating mesothelin-associated diseases and conditions (e.g.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 4, 2018
    Inventors: Daniel BATY, Patrick CHAMES, Brigitte KERFELEC, Nathalie SCHOLLER
  • ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20170190787
    Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 6, 2017
    Inventors: Daniel BATY, Patrick CHAMES, Damien NEVOLTRIS, Gérard MATHIS
  • METHODS FOR SELECTING BINDERS BY PHAGE DISPLAY AND MASKED SELECTION
    Publication number: 20170175107
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Application
    Filed: February 8, 2017
    Publication date: June 22, 2017
    Inventors: Daniel BATY, Patrick CHAMES
  • ANTIGEN BINDING FORMATS FOR USE IN THERAPEUTIC TREATMENTS OR DIAGNOSTIC ASSAYS
    Publication number: 20170152324
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Application
    Filed: February 1, 2017
    Publication date: June 1, 2017
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE
    Inventors: Daniel BATY, Patrick CHAMES, Martine MANSAIS, Brigitte KERFELEC, Caroline ROZAN
  • ANTI-MGLUR2 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
    Publication number: 20170145098
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single do main antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Application
    Filed: July 3, 2015
    Publication date: May 25, 2017
    Inventors: Daniel BATY, Jean-Philippe PIN, Patrick CHAMES, Damien NEVOLTRIS, Philippe RONDARD, Pauline SCHOLLER, Gérard MATHIS
  • Protein constructs designed for targeting and lysis of cells
    Patent number: 9644033
    Abstract: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: May 9, 2017
    Assignee: Universite De Reims Champagne Ardenne
    Inventors: Jacques Henri Max Cohen, Wael Mahmoud, Marcelle Tonye Libyh, Nathalie Godin, Annelise Gimenez, Thierry Tabary, Beatrice Donvito, Daniel Baty, Xavier Dervillez
  • Methods for selecting binders by phage display and masked selection
    Patent number: 9605257
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 28, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Single-domain antibodies that bind to HIV-1 Nef with high affinity
    Patent number: 9512203
    Abstract: The invention relates to antibody fragments with simple heavy chain or sdAbs, characterized in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: December 6, 2016
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Martine Jeanne Pierrette Chartier, Patrick Chames, Serge Salomon Benichou, Stephane Eric Ciogullari, Jerome Christophe Marie Abel Bouchet
  • ANTI-HER2 SINGLE DOMAIN ANTIBODIES, POLYPEPTIDES COMPRISING THEREOF AND THEIR USE FOR TREATING CANCER
    Publication number: 20160122432
    Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 5, 2016
    Inventors: Daniel BATY, Patrick CHAMES, Brigitte KERFELEC, Marc TURINI